INTRODUCTION
Urticaria is characterized by the rapid onset of hives (edema in superficial dermis), which may be accompanied by angioedema (edema of deep dermis, fat tissue and gastrointestinal tract). 1, 2 Hive , the dermatological lesion, consists of three typical features: (i) central edema of varying size, surrounded by reflex erythema; (ii) associated pruritus; and (iii) transient nature, with the skin returning to its normal appearance usually in a period ranging from 1 to 24 hours. 1, 2 Angioedema is defined by: (i) sudden and marked edema of the deep dermis and and fat tissue; (ii) greater frequency of pain other than pruritus; (iii) frequent involvement of mucous membranes; and (iv) resolution of the condition at approximately 72 hours, slower than with hives. [1] [2] [3] Urticaria is classified by progression as acute (up to 6 weeks)
or chronic (beyond 6 weeks of clinical course). Allergy Organization), published in 2018, was the result of a systematic with participation of experts, from several medical societies. 5 The quality of the scientific evidence was assessed per the GRA-DE (Grading of Recommendations Assessment, Development, and Evaluation) method using the GRADEpro Guideline Development Tool (GDT).
5

CLASSIFICATION
5
Chronic urticaria (CU) is subdivided into two types: "chronic spontaneous urticaria" (CSU, which is represented by urticaria with hives and/or angioedema of spontaneous onset, with an evolution of over 6 weeks, due to a known cause, such as autoreactivity, resulting from mast cells that are activated by autoantibodies, or unknown causes) and "induced urticarias" (symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, and aquagenic urticaria).
In this classification, conditions or diseases that may manifest with urticaria or angioedema, such as urticarial vasculitis, urticaria pigmentosa, autoinflammatory syndromes (in general, periodic syndromes cryopyrin-associated or Schnitzler syndrome), exercise-induced anaphylaxis, Gleich syndrome (episodic angioedema with eosinophilia), Wells syndrome (eosinophilic cellulitis), bullous pemphigoid prior to bullous lesions, angioedema mediated by non-mast cell mediators (in general, bradykinin-mediated angioedema), and other similar diseases, are not considered urticaria subtypes due to their different pathophysiological mechanisms.
DIAGNOSTIC APPROACH TO CHRONIC URTICARIA
5
The diagnostic approach was recommended to meet three main objectives: (i) to exclude differential diagnoses, (ii) to assess di- The frequency and relevance of infections vary considerably between patient groups and different areas. 5 Exclusion of malignancies with examinations is indicated only if the patient's history implicates this possibility (in general, sudden and relevant weight loss).
Plasma D-dimer levels are significantly higher in patients with active CSU and decrease according to the clinical response to treatment with omalizumab. 5 The recommendation on measuring D-dimer levels in all patients with CSU is still debated.
EVALUATION OF IMPACT OF CSU ACTIVITY AND ITS CONTROL
5
CSU activity may be evaluated using a simple unified validated system, the UAS7 score. 4, 5 UAS7 is based on the evaluation of key properties of urticaria, its signs (hives), and its symptoms (pruritus), which are documented by the patient. 5 UAS7 consists of self-assessment over a 24-hour period once a day for several days, with summing the daily scores over 7 days. Maximum score each for daily hives and symptom intensity is 3, yielding a daily total score of between 0 and 6 and a weekly score of between 0 and 42 (Chart 1 and Figure 1 ). UAS7 should be performed in the week prior to medical consultation.
It is a valuable tool for clinical evaluation of CSU .
The urticaria control test (UCT), in addition to UAS7, has become important in assessing the impact of the disease on quality of life and disease control, both in clinical practice and in research protocols. 5 UCT was developed and validated to determine the level of disease control for all forms of urticaria (CSU and induced urticaria), because UAS does not evaluate angioedema or induced urticarias. 5 UCT is composed of only four items, defining the limit between "well-controlled disease" and "poorly controlled disease;" thus, it is usable in clinical practice, with a cutoff point for "well--controlled disease" ranging from 12 and 16. 5 The score varies from 0 to 16 and higher values reflect better disease control. It is an instrument that helps guide therapeutic decisions. 5 UCT is under validation in Brazil by the Department of Allergy and Immunology of UFRJ, and the Portuguese version is described in chart 2. In order to eliminate an underlying cause, an accurate diagnosis is necessary. 5 The identification of a cause for CU, however, is difficult in most cases; for example, with infections, which may be a cause or an aggravating factor or have no relation to CU. 5 The only definitive proof of the causal nature of a suspected or triggering agent is the remission of symptoms following its removal and their recurrence following re-exposure in a double-blind challenge. 5 In practice, this approach is often not feasible. Spontaneous remission of urticaria may occur over time. Urticaria may go into remission with the elimination of a suspected cause or triggering factor coincidentally, without any cause-effect relationship. 5 Pharmacological treatment of CSU has, as main goal, to relieve symptoms by reducing the effects of mast cell mediators, such as histamine and platelet-activating factor (PAF) and others, on target organs and tissues. 5 Many symptoms of urticaria are mediated primarily by the actions of histamine on H1 receptors on endothelial cells (resulting in hives) and sensory nerves (neurogenic erythema and pruritus). 5 Thus, continuous treatment with antihistamines is fundamental in the treatment of urticaria; safety data are available for continuous use over several years. 5 Other mast cell mediators (PAF, leukotrienes, and cytokines) may be involved, and a pronounced cellular infiltrate, including basophils, lymphocytes, and eosinophils, can be seen in the lesions. 5 These patients may respond completely to a brief course of corticosteroids and be relatively refractory to antihistamines. 5 First-generation antihistamines have prominent anticholinergic effects and sedative actions on the central nervous system (CNS) and have many interactions with alcohol and drugs that affect the CNS, such as analgesics, hypnotics, sedatives, and mood--altering substances. 5 They can interfere with rapid eye movement sleep (REM sleep) and impact learning and cognitive performance. The recommended treatment algorithm for CU, per the 2018
MANAGEMENT OF PATIENTS WITH URTICARIA
International Guideline, is summarized in figure 2 . tadine, epinastine and bilastine. 5 Their efficacies are similar; however, due to the absence of hepatic metabolism, fexofenadine, desloratadine, and bilastine are indicated in liver diseases. Although antihistamines achieve CSU control when used at up to 4-fold the licensed doses, in many patients with CSU, alternative treatments may be required. Before changing the treatment to alternative therapies (adjuvants), it is recommended to wait 1-4 weeks to achieve complete effectiveness of the drugs that are in use. 5 Because the severity of urticaria may vary and because spontaneous remission may occur over time, therapeutic re-evaluation of the need for continued treatment or a separate or adjunctive treatment is also recommended every 3 to 6 months. 
Third-line pharmacological treatment:
In recent years, the use of biological agents for urticaria, particularly omalizumab, has become more prominent as a third-line agent in chronic urticaria that is refractory to initial approaches (first-and second-lines of treatment). 18 Omalizumab is a humanized monoclonal antibody against the cε3 domain of IgE, which lies near the binding site for FcεRI receptors on mast cells and basophils and
FcεRII. 5 The doses of omalizumab that have been used in several studies for chronic refractory urticaria have ranged from 150-300mg
subcutaneously, once a month; ideal dose for urticaria is 300mg every 4 weeks. 5 On average, half of all patients (52%) controlled their urticaria (UAS7 ≤ 6) after the 12 th week versus 62% after the 24 th week in phase III studies of the molecule; 11% did not respond to treatment. 19 Initial treatment should be continued for 24 weeks. 19 The total treatment duration for chronic urticaria has not been established; thus, the decision to discontinue treatment should be individualized.
The proposed mechanism of action for this drug is based on the finding that when there are high circulating IgE levels in the blood, mast cells and basophils express higher amounts of FcεRI receptors on their membranes, becoming vulnerable to binding with anti-FcεRIα IgG autoantibodies. Doses of omalizumab in CSU independent of serum IgE levels. The approved doses, and the treatment duration may vary by country. 5 In Brazil, omalizumab was approved for CSU in children aged over 12 years, at 300 mg subcutaneously every 4 weeks for 6 consecutive months.
Treatment of Exacerbations
Oral corticosteroids, particularly prednisone at doses of 20-50mg per day, may be necessary for short periods of use (7 days, maximum 10 days) for significant exacerbations of chronic urticaria that does not respond completely to antihistamines or for sporadic episodes of exacerbation. 5 Prolonged use should be avoided due to the side effects and development of comorbidities. 5 Their use should be avoided for more than 7 days each month. There is a strong recommendation for only using systemic corticosteroids under specialist supervision in the treatment of CSU. 
Fourth-line pharmacological treatments
Despite the absence of strong published scientific evidence, all fourth-line drugs may be valuable for patients in certain cases of refractoriness in the earlier stages, in the appropriate clinical settings. 5 In patients with severe disease and persistent progression, with treatment failure to previous measures, cyclosporine therapy is an option to refractory CSU. Cyclosporine acts by inhibiting IL-2 production in lymphocytes. In urticaria, it is believed that an additional mechanism of action is its reduction of immunoglobulin production and reduction of the high-affinity IgE receptor. It has been studied in cohorts and placebo-controlled studies at doses of 1 to 5mg/kg/day. The effective dose in chronic urticaria appears to be 3 mg/kg/day for periods of 8 to 16 weeks, yielding success rates of 64% to 95%. 20, 21 It is important to emphasize that before use, patients should perform blood pressure measures and evaluate renal function, magnesium, uric acid, and potassium; these tests should be repeated periodically. 20 Side effects appear to be dose-dependent and occur in more than half of all patients who are treated with moderate doses (4 to 5mg/kg/day).
21
Other Treatments
Other non-licensed medications should be used in patients in whom previous steps of treatment failed. They have a low level of recommendation and have only been presented in case reports and studies of small series. to 50% of patients who did not responded to therapy with antihistamines alone. 25 Reeves et al. 26 studied 18 CU patients who had been treated with hydroxychloroquine for 12 weeks, noting disease control and improved quality of life. This drug is relatively safe, but the possibility of retinopathy should be monitored.
b)
Other Immunosuppressants -Methotrexate has been used at a mean weekly dose of 15 mg. 27 This drug has anti-inflammatory and immunomodulatory properties, and its mechanism of action comprises an increase in adenosines, apoptosis of CD4 lymphocytes, and inhibition of neutrophil chemotaxis. 27, 28 -Other oral drugs, with immunomodulatory and immunossupressive effects, such as sulfasalazine, mycophenolate mofetil, azathioprine, cyclophosphamide, and tacrolimus. are available for use in CSU. 5 There are no controlled studies, with relevant number of patients and efficacy; they mau be used as alternatives on failure with conventional therapy. been used in urticaria due to inflammatory cytokine production in the disease. 29 Canakinumab is under investigation in a placebo-controlled study, but the results have not been made available. There are few case reports using this drug. 
Second-line of treatment
As second-line of treatment up-dosing (up to 4-fold) of second-generation antihistamines is indicated; furthermore, add other sgAH, H2-antagonists, anti-leukotriene (montelukast) or first-generation antihistamines at bedtime.
Third-line treatment
If there is no control with the previous steps, hydroxyzine or doxepin are indicated, as third-line treatment. 
Fourth-line treatment
Pregnancy and lactation
Regarding treatment during gestation, to date, there are no reports of congenital defects in women who have used second-generation anti-H1 antihistamines during pregnancy. 5 However, few studies are available regarding the use of cetirizine, 33 and a large meta-analysis has examined the use of loratadine. 34 Loratadine is metabolized in the liver, whereas desloratadine is not. 5 Due to safety profile, the preferred second-generation anti-histamines in pregnacy are loratadine, (with possible extrapolation to desloratadine) and cetirizine (with possible extrapolation to levocetirizine). 5 All anti-H1
antihistamines are excreted in human milk at low concentrations. First-generation anti-H1s should be avoided during breastfeeding. In private care, of the therapeutic options that are offered to patients with CSU, 94% used non-sedating antihistamines as the first option versus 6% for sedating antihistamines. As the second option, 81% administered non-sedating antihistamines at doses of 1 to 4-folds the licensed dose, compared with 13% for sedating antihistamines and 6% for omalizumab. Subsequent options included cyclosporine, dapsone, systemic corticosteroid (short-term), methotrexate and montelukast.
Regarding the side effects of medications, 56% of participants questioned the safety of continuous prescription of sedating antihistamines (first-generation). Further, 81% of participants opined that the prescription of non-sedating antihistamines at doses higher than those licensed was safe.
Regarding the indications for omalizumab use, when the antihistamines that were used did not show significant efficacy, 69%
of participants favored its use, despite its high cost.
For other treatment options, after non-sedating antihistamines and omalizumab, participants indicated dapsone, colchicine, methotrexate, H2 antihistamines, cyclosporine, and montelukast.
Regarding lifestyle habits for CSU patients, 81% of participants suggested that patients should avoid use of nonhormonal anti-inflammatory drugs; 50% advised that foods with dyes and For the evaluation of CSU activity, 62% of participants indicated the use of the UAS-7 form but noted inadequate comprehension and completion by many patients with CSU. 
CONCLUSIONS
Other adjuvant drugs are available for off-label use in
Brazil; thus, they may be useful and necessary for refractory cases of CSU, with strict clinical and laboratory monitoring and information of the possible benefits and risks when using them.q
